Trial Profile
A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; PF-06821497 (Primary) ; Carboplatin; Cisplatin; Etoposide
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Prostate cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 23 Jun 2023 Planned End Date changed from 23 Nov 2025 to 24 Oct 2025.
- 23 Jun 2023 Planned primary completion date changed from 23 Nov 2025 to 24 Oct 2025.
- 19 May 2023 Planned End Date changed from 13 Apr 2025 to 23 Nov 2025.